STAT+: Argenx sees unusual setback with failure of late-stage study of drug for autoimmune disease
Argenx said Thursday that its blockbuster drug Vyvgart didn’t outperform placebo in a Phase 3 trial of patients with Sjögren’s disease, a chronic autoimmune disorder. It’s an unusual setback for Argenx, which has racked up a series of wins in…
ImpactNotable 33/100
Why it mattersRule-based estimate: no strong signals; trust 8/10.
RegionsGlobal
Published8 h ago (Thu, 08 Oct 2026 14:02:29 GMT)
RetrievedThu, 08 Oct 2026 16:00:17 GMT via rss
ClassifiedThu, 08 Oct 2026 16:00:35 GMT by heuristic
AuthorJason Mast